AGIO

Agios Pharmaceuticals Inc.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$605.5M

Burn Rate (Qtr)

$99M

Company Profile

For more than a decade, our mission has been to create differentiated, small molecule medicines for patients in three focus areas – malignant hematology, solid tumors and rare genetic diseases – based on our unique expertise in cellular metabolism and adjacent areas of biology.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Tibsovo (Ivosidenib )

Acute Myeloid Leukemia (AML) with IDH1 mutation

Quarterly Sales (Approved)

February 12, 2021 (Est)

Vorasidenib (IDH1/IDH2 inhibitor)

Low-Grade Glioma

Phase 3 to be Initiated

TBD

Mitapivat (pyruvate kinase R (PKR) activator)

Sickle Cell Disease

Phase 3 to be Initiated

H1 2020

Ivosidenib (ClarIDHy)

Advanced Cholangiocarcinoma

sNDA Submission

Q1 2020

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon